Portal de Periódicos da CAPES

Targeting human TLRs to combat COVID‐19: A solution?

2020; Wiley; Volume: 93; Issue: 2 Linguagem: Inglês

10.1002/jmv.26387

1096-9071

Ritwik Patra, Nabarun Chandra Das, Suprabhat Mukherjee,

Immune Response and Inflammation

Journal of Medical VirologyVolume 93, Issue 2 p. 615-617 LETTER TO THE EDITOR Targeting human TLRs to combat COVID-19: A solution? Ritwik Patra, Ritwik Patra Integrative Biochemistry & Immunology Laboratory, Department of Animal Science, Kazi Nazrul University, Asansol, West Bengal, IndiaSearch for more papers by this authorNabarun Chandra Das, Nabarun Chandra Das Integrative Biochemistry & Immunology Laboratory, Department of Animal Science, Kazi Nazrul University, Asansol, West Bengal, IndiaSearch for more papers by this authorSuprabhat Mukherjee, Corresponding Author Suprabhat Mukherjee [email protected] [email protected] orcid.org/0000-0002-5709-9190 Integrative Biochemistry & Immunology Laboratory, Department of Animal Science, Kazi Nazrul University, Asansol, West Bengal, India Correspondence Suprabhat Mukherjee, Department of Animal Science, Kazi Nazrul University, Asansol, West Bengal 713 340, India. Email: [email protected] and [email protected]Search for more papers by this author Ritwik Patra, Ritwik Patra Integrative Biochemistry & Immunology Laboratory, Department of Animal Science, Kazi Nazrul University, Asansol, West Bengal, IndiaSearch for more papers by this authorNabarun Chandra Das, Nabarun Chandra Das Integrative Biochemistry & Immunology Laboratory, Department of Animal Science, Kazi Nazrul University, Asansol, West Bengal, IndiaSearch for more papers by this authorSuprabhat Mukherjee, Corresponding Author Suprabhat Mukherjee [email protected] [email protected] orcid.org/0000-0002-5709-9190 Integrative Biochemistry & Immunology Laboratory, Department of Animal Science, Kazi Nazrul University, Asansol, West Bengal, India Correspondence Suprabhat Mukherjee, Department of Animal Science, Kazi Nazrul University, Asansol, West Bengal 713 340, India. Email: [email protected] and [email protected]Search for more papers by this author First published: 04 August 2020 https://doi.org/10.1002/jmv.26387Citations: 83Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Choudhury A, Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs. J Med Virol. 2020: 1-9. https://doi.org/10.1002/jmv.25987 PubMedWeb of Science®Google Scholar 2Bonam SR, Kaveri SV, Sakuntabhai A, Gilardin L, Bayry J. Adjunct immunotherapies for the management of severely ill COVID-19 patients. Cell Reports Med. 2020; 1:100016. https://doi.org/10.1016/j.xcrm.2020.100016 10.1016/j.xcrm.2020.100016 PubMedGoogle Scholar 3Lucchesi A, Silimbani P, Musuraca G, et al. Clinical and biological data on the use of hydroxychloroquine against SARS-CoV-2 could support the role of the NLRP3 inflammasome in the pathogenesis of respiratory disease. J Med Virol. 2020. https://doi.org/10.1002/jmv.26217 10.1002/jmv.26217 PubMedWeb of Science®Google Scholar 4Li H, Liu L, Zhang D, et al. Hypothesis SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020; 395: 1517-1520. https://doi.org/10.1016/S0140-6736(20)30920-X 10.1016/S0140-6736(20)30920-X CASPubMedWeb of Science®Google Scholar 5Mukherjee S, Huda S, Sinha Babu SP. TLR polymorphism in host immune response to infectious diseases: a review. Scand J Immunol. 2019; 90:e12771. https://doi.org/10.1111/sji.12771 10.1111/sji.12771 PubMedWeb of Science®Google Scholar 6Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020; 20: 355-362. https://doi.org/10.1038/s41577-020-0331-4 10.1038/s41577-020-0331-4 CASPubMedWeb of Science®Google Scholar 7Cao W, Li T. COVID-19: towards understanding of pathogenesis. Cell Res. 2020; 30: 367-369. https://doi.org/10.1038/s41422-020-0327-4 10.1038/s41422-020-0327-4 CASPubMedWeb of Science®Google Scholar 8Achek A, Yesudhas D, Choi S. Toll-like receptors: promising therapeutic targets for inflammatory diseases. Arch Pharm Res. 2016; 39: 1032-1049. https://doi.org/10.1007/s12272-016-0806-9 10.1007/s12272-016-0806-9 CASPubMedWeb of Science®Google Scholar 9Mukherjee S, Karmakar S, Sinha Babu SP. TLR2 and TLR4 mediated host immune responses in major infectious diseases: a review. Braz J Infect Dis. 2016; 20: 193-204. https://doi.org/10.1016/j.bjid.2015.10.011 10.1016/j.bjid.2015.10.011 PubMedWeb of Science®Google Scholar 10Kalita P, Padhi AK, Zhang KYJ, Tripathi T. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2. Microb Pathog. 2020; 145:104236. https://doi.org/10.1016/j.micpath.2020.104236 10.1016/j.micpath.2020.104236 CASPubMedWeb of Science®Google Scholar 11Bhattacharya M, Sharma AR, Patra P, et al. Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): immunoinformatics approach. J Med Virol. 2020; 92: 618-631. https://doi.org/10.1002/jmv.25736 10.1002/jmv.25736 CASPubMedWeb of Science®Google Scholar Citing Literature Volume93, Issue2Special Issue on New coronavirus (2019‐nCoV or SARS‐CoV‐2) and the outbreak of the respiratory illness (COVID‐19): Part‐IXFebruary 2021Pages 615-617 ReferencesRelatedInformation